Infusion Center Valuation & Sale Process
Infusion is one of the fastest-growing segments of specialty healthcare, and private equity is consolidating it quickly, with 11 platform deals announced in 2024 alone. If you own an ambulatory or home infusion business, the first question to answer is what it is worth today, and which levers move that number most.
Free valuation calculator What moves your number Jump to FAQs
No upfront fee. No obligation. Success-based, confidentiality-first advisory.
Why is infusion center valuation different?
Infusion center valuation is different because the drug mix and the payer contracts behind it largely determine the multiple. A center weighted toward high-margin specialty biologics with strong commercial contracts is underwritten very differently from one built on general hydration and antibiotics under thin payer rates.
As of June 2026, single-site ambulatory infusion centers generally trade in the 5.0x to 8.0x EBITDA range, multi-location operations 10.0x to 14.0x, and fully scaled national platforms 14.0x to 20.0x or higher. These are ranges, not promises. Where you land depends on therapy mix, payer diversity, referral concentration, and how efficiently you run labor.
Therapy mix
Specialty biologics in rheumatology, oncology, and neurology carry far higher margins than general hydration, and buyers pay for that mix.
Payer and referral diversity
Favorable, varied commercial contracts and a broad referral base lower the risk that one change resets your revenue.
Operating efficiency
Labor runs 35 to 50 percent of revenue. Efficient chair utilization and staffing are what separate 25 to 30 percent margins from 15 percent.
What do buyers look for in an infusion acquisition?
Buyers look for durable, high-margin therapy revenue with payer diversity and operations that scale. The most active acquirers are private-equity-backed infusion platforms, home-health consolidators, and specialty pharmacy operators adding infusion capacity.
- A high-margin specialty biologics mix — rheumatology, oncology, and neurology rather than commoditized hydration.
- Diversified, favorable payer contracts — strong commercial rates and limited exposure to any single payer.
- Low referral concentration — no single physician group or source above roughly 20 percent of volume.
- Multiple revenue centers — infusion administration plus specialty pharmacy or nursing services where applicable.
- Recurring chronic patients — long-term therapy patients who deliver predictable, repeat revenue.
- Efficient, compliant operations — strong chair utilization, clean documentation, and audit readiness.
What drives an infusion center’s valuation multiple?
The multiple a buyer applies reflects margin durability and concentration risk. These are the levers that move it most, and shifting therapy mix toward specialty biologics is often the highest-impact one.
| Value driver | Effect on multiple | Why buyers care |
|---|---|---|
| High-margin specialty biologics mix | Raises | Durable margin in rheum, onc, and neuro therapies |
| Diversified, favorable payer contracts | Raises | Revenue is not exposed to one payer’s rate change |
| Recurring chronic patient base | Raises | Predictable, repeat revenue over years |
| Single-payer or single-referral concentration | Lowers | One change can reset a large share of revenue |
| Labor inefficiency (low utilization) | Lowers | Labor is 35–50% of revenue and compresses margin |
Directional effect on infusion multiples, as of mid-2026. Sources: FOCUS Investment Banking infusion market update, Q1 2025. Most of these levers can be improved in the 12 months before a sale.
How does the sale process work?
A confidential process typically runs 6 to 9 months from valuation to close. Starting with a baseline valuation 12 months ahead gives you time to improve therapy mix, diversify payers, and tighten utilization before going to market.
Baseline value + prep plan
We rebuild adjusted EBITDA, map therapy and payer mix, and target the levers that lift your multiple most.
Confidential marketing
We approach qualified platforms and strategic buyers behind NDAs, protecting your staff and referral relationships.
Diligence + close
We manage clinical, payer, and financial diligence, negotiate terms, and guide the transition so value holds.
What should infusion owners know about the market?
The shift of infusion care out of hospitals and into lower-cost ambulatory and home settings continues to drive growth, and the US infusion market is large and expanding at roughly 8 to 10 percent a year. Consolidation is accelerating, which means a prepared owner usually has several competing acquirers rather than one.
EBITDA range, from single sites to scaled national platforms
annual growth in a roughly $120B US infusion market
infusion platform deals announced in 2024 as consolidation accelerated
Sources: FOCUS Investment Banking infusion therapy services market update, Q1 2025; Straits Research home infusion therapy market.
See where your infusion business stands
Start with a confidential estimate, then test the number against live buyer demand. A valuation is a planning tool. It commits you to nothing.
No upfront fee. No obligation.
Resources to go deeper
Infusion center valuation & selling FAQs
How is an infusion center valued?
An infusion center is valued by normalizing earnings into adjusted EBITDA, applying a market multiple for your size and therapy mix, and adjusting for the risks a buyer tests in diligence, chiefly payer and referral concentration, drug-margin durability, and labor efficiency.
What multiple do infusion businesses sell for?
As of June 2026, single-site ambulatory infusion centers generally sell for 5.0x to 8.0x EBITDA, multi-location operations 10.0x to 14.0x, and fully scaled national platforms 14.0x to 20.0x or higher, depending on therapy mix, payer diversity, and operating efficiency.
How does a specialty-biologics mix raise value?
Specialty biologics in rheumatology, oncology, and neurology carry materially higher margins than general hydration or antibiotics, so a center weighted toward them produces more durable EBITDA, which buyers reward with a higher multiple.
How does payer concentration affect valuation?
Heavy reliance on a single payer or referral source is a discount, because one rate change or lost contract can reset a large share of revenue. A diversified payer mix with favorable commercial contracts supports the top of the range.
Who buys infusion centers and home infusion businesses?
The most active buyers are private-equity-backed infusion platforms, home-health consolidators, and specialty pharmacy operators adding infusion capacity. The right buyer depends on your setting, therapy mix, and scale.
Will a valuation obligate me to sell?
No. A valuation is confidential and carries no obligation. It is a planning tool that tells you what your business is worth today and what would make it worth more, so any future decision is yours to make on your own timeline.
Find out what your infusion business is worth
Vallexa Advisors is a healthcare-only M&A firm. We help owners understand value, prepare intelligently, and run a confidential sale process that attracts qualified buyers.
No upfront fee. No obligation. 100% success-based.
Educational only. Not legal, financial, or tax advice. Infusion M&A outcomes depend on specific facts, payer mix, therapy mix, market conditions, and regulatory context. Speak with qualified counsel before acting on anything on this page.
- Home Health Agency Valuation & Sale Process (Owner Guide) | Vallexa Advisors
- Hospice Valuation & Selling Guide (for Owners)
- Home Care Business Valuation & Selling Guide (Private Duty / Non-Medical)
- Behavioral Health Practice Valuation & Sale Process
- Med Spa Valuation & Sale Process
- HRT & Longevity Clinic Valuation
- RCM / Medical Billing Company Valuation
- Dental Practice Valuation & DSO Sale
- Clinical Research Site Valuation & Sale Process
Estimated reading time: 6 minutes